Monthly Drifts in Fate Therapeutics Inc (FATE) Stock: A Closer Look

Fate Therapeutics Inc [FATE] stock prices are up 1.87% to $1.09 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The FATE shares have gain 18.30% over the last week, with a monthly amount drifted -5.22%, and not seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Fate Therapeutics Inc [NASDAQ: FATE] stock has seen the most recent analyst activity on November 18, 2024, when BofA Securities upgraded its rating to a Neutral. Previously, Piper Sandler upgraded its rating to Overweight on June 17, 2024, and elevated its price target to $6. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $7 on January 24, 2023. Wedbush downgraded its rating to a Neutral and reduced its price target to $7 on January 06, 2023. Truist downgraded its rating to Hold for this stock on January 06, 2023, and downed its price target to $7. In a note dated January 06, 2023, Stifel downgraded an Hold rating on this stock and revised its target price from $107 to $5.30.

The stock price of Fate Therapeutics Inc [FATE] has been fluctuating between $0.66 and $4.20 over the past year. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Fate Therapeutics Inc [NASDAQ: FATE] shares were valued at $1.09 at the most recent close of the market. An investor can expect a potential return of 175.23% based on the average FATE price forecast.

Analyzing the FATE fundamentals

The Fate Therapeutics Inc [NASDAQ:FATE] reported sales of 8.47M for trailing twelve months, representing a drop of -71.84%. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -22.71%, Pretax Profit Margin comes in at -20.25%, and Net Profit Margin reading is -20.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.56 and Total Capital is -0.56. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.31.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0617 points at the first support level, and at 1.0333 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1367, and for the 2nd resistance point, it is at 1.1833.

Ratios To Look Out For

It’s worth pointing out that Fate Therapeutics Inc [NASDAQ:FATE]’s Current Ratio is 8.04. In addition, the Quick Ratio stands at 8.04 and the Cash Ratio stands at 1.44. Considering the valuation of this stock, the price to sales ratio is 14.84, the price to book ratio is 0.48.

Transactions by insiders

Recent insider trading involved TAHL CINDY, that happened on Aug 04 ’25 when 9037.0 shares were sold. President and CEO, Valamehr Bahram completed a deal on Aug 04 ’25 to sell 14466.0 shares. Meanwhile, Officer TAHL CINDY bought 9037.0 shares on Aug 04 ’25.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.